(Q33227741)

24 July 2017

1 reference

title

Ribonucleases as a novel pro-apoptotic anticancer strategy: review of the preclinical and clinical data for ranpirnase (English)

1 reference

24 July 2017

0 references

2

David Sidransky

1 reference

24 July 2017

John Costanzi

1

1 reference

24 July 2017

Ami Navon

series ordinal

3

1 reference

24 July 2017

Howard Goldsweig

series ordinal

4

1 reference

24 July 2017

language of work or name

1 reference

1 January 2005

1 reference

24 July 2017

1 reference

24 July 2017

volume

23

1 reference

24 July 2017

issue

7

1 reference

24 July 2017

page(s)

643-650

1 reference

Cancer chemotherapy--ribonucleases to the rescue

24 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F07357900500283143

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900500283143

Characterization of the mechanism of cellular and cell free protein synthesis inhibition by an anti-tumor ribonuclease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900500283143

Association of p53 gene mutation with decreased chemosensitivity in human malignant gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900500283143

Antineoplastic ribonucleases selectively kill thyroid carcinoma cells via caspase-mediated induction of apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900500283143

Tumoricidal effects of onconase on various tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900500283143

Induction of differentiation of leukaemic (HL-60) or prostate cancer (LNCaP, JCA-1) cells potentiates apoptosis triggered by onconase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900500283143

Enhancement of vincristine cytotoxicity in drug-resistant cells by simultaneous treatment with onconase, an antitumor ribonuclease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900500283143

G1 arrest of U937 cells by onconase is associated with suppression of cyclin D3 expression, induction of p16INK4A, p21WAF1/CIP1 and p27KIP and decreased pRb phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900500283143

Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900500283143

Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900500283143

Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900500283143

Caelyx in malignant mesothelioma: a phase II EORTC study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900500283143

A phase II trial of ifosfamide/mesna with doxorubicin for malignant mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900500283143

Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900500283143

A phase II trial of dose-escalated doxorubicin and ifosfamide/mesna in patients with malignant mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900500283143

High-dose doxorubicin, dexrazoxane, and GM-CSF in malignant mesothelioma: a phase II study-Cancer and Leukemia Group B 9631.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900500283143

Malignant mesothelioma. The Eastern Cooperative Oncology Group (ECOG) experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900500283143

Combined regimen of cisplatin, doxorubicin, and alpha-2b interferon in the treatment of advanced malignant pleural mesothelioma: a Phase II multicenter trial of the Italian Group on Rare Tumors (GITR) and the Italian Lung Cancer Task Force (FONICAP)

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900500283143

Prospective study of combination chemotherapy with cyclophosphamide, doxorubicin, and cisplatin for unresectable or metastatic malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900500283143

Phase II trial of pegylated-liposomal doxorubicin (Doxil) in mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900500283143

The value of adriamycin in the treatment of diffuse malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900500283143

Potent and specific antitumor effects of an anti-CD22-targeted cytotoxic ribonuclease: potential for the treatment of non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900500283143

Specifically targeting the CD22 receptor of human B-cell lymphomas with RNA damaging agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900500283143

Highly selective toxic and proapoptotic effects of two dimeric ribonucleases on thyroid cancer cells compared to the effects of doxorubicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900500283143

The development of proteasome inhibitors as anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900500283143

10.1080/07357900500283143

21 January 2018

Identifiers

DOI

1 reference

24 July 2017

1 reference